Dyne Therapeutics slips after $200 mln stock offering launch

Shares of Dyne Therapeutics DYN.O down 7.8% to $8.78 post-market as co looks to raise equity

Co focused on neuromuscular diseases commences $200 mln stock offering

Morgan Stanley, Jefferies, Stifel and Guggenheim are jt bookrunners

Waltham, Massachusetts-based firm also announces it secured up to $275 mln in debt financing from Hercules Capital

With ~113.7 mln shares outstanding, DYN has $1.1 bln market cap

DYN shares on Mon closed down 0.5% at $9.52

On Jun 17, stock fell 21% to close at $10.86 after co revised timelines for its genetic disorder therapy following meeting with the FDA

Through Mon, stock has shed ~60% YTD